申请人:Chen Huifen
公开号:US20110118230A1
公开(公告)日:2011-05-19
The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
本发明涉及式(I),(I-a)和(I-b)的1,7-二氮杂咔唑化合物,其作为激酶抑制剂有用,更具体地作为检查点激酶1(chk1)抑制剂有用,因此可用作癌症治疗剂。本发明还涉及包含这些化合物的组合物,更具体地是药物组合物,并使用它们治疗各种形式的癌症和增生性疾病的方法,以及使用这些化合物进行哺乳动物细胞的体外、原位和体内诊断或治疗的方法,或相关的病理条件。